In Alzheimer's disease (AD) models, melatonin administration (10 mg/kg, intraperitoneally, daily for 4 weeks) reduced P‐tau and Aβ plaque accumulation, improving cognitive function and mitophagy.208. Here, MAPT is linked to early-onset autosomal dominant Alzheimer disease.